Abstract: The present invention provides an N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.
Type:
Grant
Filed:
October 13, 2009
Date of Patent:
February 11, 2014
Assignees:
Hanall Biopharma Co., Ltd., Korea Research Institute of Chemical Technology
Inventors:
Sung Wuk Kim, Sung Soo Jun, Hyae Gyeong Cheon, Kwang Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong Cheol Lee
Abstract: Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
February 4, 2014
Assignee:
Hanall Biopharma Co., Ltd.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jae Woon Son
Abstract: The present invention provides an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.
Type:
Grant
Filed:
October 13, 2009
Date of Patent:
February 4, 2014
Assignees:
Hanall Biopharma Co., Ltd., Korea Research Institute of Chemical Technology
Inventors:
Sung Wuk Kim, Sung Soo Jun, Hyae Gyeong Cheon, Kwang Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong Cheol Lee
Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.
Type:
Grant
Filed:
December 21, 2011
Date of Patent:
December 31, 2013
Assignee:
Hanall Biopharma Co., Ltd.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
Abstract: The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
September 24, 2013
Assignee:
Hanall Biopharma Co., Ltd.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Young Woong Kim
Abstract: The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof.
Type:
Application
Filed:
September 7, 2011
Publication date:
September 12, 2013
Applicant:
HANALL BIOPHARMA CO., LTD.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
Abstract: A pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof, which is capable of treating or preventing side effects such as muscle toxicity caused by administering a statin-based lipid-lowering drug, and a pharmaceutical combination composition comprising a statin drug and a losartan drug as active ingredients are provided. The pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof provides an effect on treating or preventing muscle-related side effects caused by administration of a statin drug for treating hyperlipidemia, as well as an intrinsic pharmacological effect for treating or preventing hypertension. When administered along with a statin drug in sequence or co-administered at the same time with the statin drug, the pharmaceutical composition can exhibit an effect of effectively or significantly decreasing or preventing side effects such as muscle toxicity.
Type:
Application
Filed:
March 28, 2012
Publication date:
June 20, 2013
Applicant:
HANALL BIOPHARMA CO., LTD.
Inventors:
Sung Wuk KIM, Seong Choon CHOE, Chang Hee MIN, Soon Im LEE, Ja Seong KOO, Sang Ouk SUN, Na Young LEE
Abstract: The present invention relates to a composition for external application for improving a skin disease (e.g. psoriasis). The composition contains adenosylcobalamin (coenzyme B12), optionally in admixture with other cobalamins. The composition can be present in the form of liposomal preparations, which are made of a phospholipid and cholesterol.
Type:
Application
Filed:
November 16, 2012
Publication date:
April 4, 2013
Applicants:
HANALL BIOPHARMA CO., LTD., KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
Inventors:
Korea Research Institute of Chemical Technology, HANALL BIOPHARMA CO., LTD.
Abstract: A method of treating mild atopic dermatitis patients by locally administering an external composition containing adenosylcobalamin as an active ingredient is provided. The composition can effectively treat mild atopic dermatitis patients without side effects.
Abstract: Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.
Type:
Grant
Filed:
May 11, 2011
Date of Patent:
March 12, 2013
Assignee:
Hanall Biopharma Co., Ltd.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jae Woon Son
Abstract: A biguanide derivative compound with N4-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
Type:
Application
Filed:
January 6, 2011
Publication date:
December 6, 2012
Applicant:
HANALL BIOPHARMA CO., LTD.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
Type:
Application
Filed:
January 6, 2011
Publication date:
November 8, 2012
Applicant:
HANALL BIOPHARMA CO., LTD.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Young Woong Kim, Min Seok Kang, Byung Kyu Oh, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.
Type:
Application
Filed:
December 21, 2011
Publication date:
November 1, 2012
Applicant:
HANALL BIOPHARMA CO., LTD.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
Abstract: The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.
Type:
Application
Filed:
October 19, 2010
Publication date:
October 4, 2012
Applicant:
HANALL BIOPHARMA CO., LTD.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
Type:
Grant
Filed:
January 25, 2011
Date of Patent:
July 17, 2012
Assignee:
HanAll BioPharma Co., Ltd.
Inventors:
Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
Abstract: The present invention provides metformin butyric acid salt, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin butyric acid salt according to the present invention has an excellent pharmacological effect as compared with metformin hydrochloride and is capable of achieving a therapeutic purpose by administering an amount less than metformin hydrochloride. Furthermore, the metformin butyric acid salt has excellent physicochemical properties, such as solubility, stability, hygroscopicity and adsorption preventing property, in processibility of formulations and thereby is capable of being usefully utilized as a pharmaceutically acceptable salt of the metformin.
Type:
Application
Filed:
July 16, 2010
Publication date:
May 31, 2012
Applicant:
Hanall Biopharma Co., Ltd.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Changhee Min, Min Seok Kang, Yong Eun Kim, Ja Seong Koo
Abstract: Modified erythropoietin polypeptides that include the mutation R131Q, and uses thereof are provided. Also provided are pharmaceutical compositions, including compositions formulated for oral administration, that contain the modified erythropoietin polypeptides and uses of the compositions to treat diseases and conditions treated by erythropoietin.
Type:
Grant
Filed:
June 6, 2008
Date of Patent:
February 14, 2012
Assignee:
HanAll BioPharma Co., Ltd.
Inventors:
Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
Abstract: Protease resistant modified interferon-beta polypeptides, and pharmaceutical compositions containing such modified interferon-beta polypeptides are provided. The modified interferon-beta polypeptides contain amino acid substitutions that confer increased resistance to proteolysis over unmodified IFN beta cytokine molecules. The present invention provides for pharmaceutical formulations suitable for oral, nasal and pulmonary administration, and the use of such formulations in the treatment of disease.
Type:
Grant
Filed:
January 26, 2011
Date of Patent:
January 31, 2012
Assignee:
Hanall Biopharma Co., Ltd.
Inventors:
Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
Abstract: The invention concerns human thrombopoietin and in particular modified forms of thrombopoietin (TPO) with improved properties. The improved proteins contain amino acid substitutions at specific positions within the TPO molecule. The invention provides modified TPO molecules, preferably fusion proteins comprising immunoglobulin constant regions and modified human TPO, with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in the treatment of diseases in humans.
Type:
Application
Filed:
January 20, 2010
Publication date:
December 1, 2011
Applicant:
HANALL BIOPHARMA CO., LTD.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Jae Kap Jeong, Sung Yul Lee, Yeon Jung Song, Won Jo Shim